GSK’s influenza vaccine is approved for use in the US

Hannah Blake

pharmaphorum

GSK’s influenza vaccine, Fluarix Quadrivalent, has been approved by the US FDA for the immunisation of adults and children aged three years and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B. Fluarix Quadrivalent is the first intramuscular vaccine to cover against four influenza strains.

“Trivalent influenza vaccines have helped protect millions of people against flu, but in six of the last 11 flu seasons, the predominant circulating influenza B strain was not the strain that public health authorities selected. Fluarix Quadrivalent will help protect individuals against both B strains and from a public-health standpoint, can help decrease the burden of disease.”

Dr. Leonard Friedland, V.P. and Head, GSK North America Vaccines Clinical Development and Medical Affairs.

GSK will make Fluarix Quadrivalent available in time for the 2013-14 flu seasons and also plans to fulfill orders for its trivalent vaccines. Healthcare providers traditionally order flu vaccines about a year in advance of each flu season.

&nbsp,

Euro-Africa-health-Investment-March-26-27-2013

&nbsp,

Related news:

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu (News-medical net)

Reference links:

GSK press release 

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.